{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:51:52Z","timestamp":1793379112631,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007419.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000}}],"reference-count":188,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007419.pub7","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T07:51:11Z","timestamp":1687852271000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Gianni","family":"Virgili","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA); University of Florence; Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Curran","sequence":"additional","affiliation":[{"name":"Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersilia","family":"Lucenteforte","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine; University of Pisa; Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[{"name":"Centre for Public Health; Queen's University Belfast; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[{"name":"Ophthalmology; Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmolologia-IRCCS; Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"issue":"19","key":"10.1002\/14651858.CD007419.pub7-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ophtha.2010.03.045","article-title":"A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2","volume":"117","author":"Michaelides","year":"2010","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","article-title":"A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3","volume":"130","author":"Rajendram","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e72755","DOI":"10.1371\/journal.pone.0072755","article-title":"Structural and functional measures of efficacy in response to bevacizumab monotherapy in diabetic macular oedema: exploratory analyses of the BOLT Study (Report 4)","volume":"8","author":"Sivaprasad","year":"2013","journal-title":"PloS ONE"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/15569527.2020.1802741","article-title":"Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors","volume":"39","author":"Chatzirallis","year":"2020","journal-title":"Cutaneous and Ocular Toxicology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.ophtha.2011.02.018","article-title":"The DAVINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema","volume":"118","author":"Do","year":"2011","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0008|cit8","first-page":"1652","article-title":"Erratum: Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: Randomized clinical trial (JAMA Ophthalmology (2013) 131:10 (1339-1347) DOI: 10.1001\/jamaophthalmol.2013.4592)","volume":"131","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Archives of Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.ophtha.2012.01.049","article-title":"Cost-effectiveness analysis of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"119","author":"Dewan","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1064\u201377","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ophtha.2012.08.022","article-title":"Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results","volume":"119","author":"Elman","year":"2012","journal-title":"Ophthalmology"},{"issue":"13","key":"10.1002\/14651858.CD007419.pub7-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub7-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1586\/17469899.2014.900439","article-title":"Treatment of macular edema in diabetic retinopathy: Comparison of the efficacy of intravitreal bevacizumab and ranibizumab injections","volume":"9","author":"Ekinci","year":"2014","journal-title":"Expert Review of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two Phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00417-018-04213-x","article-title":"Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study","volume":"257","author":"Li","year":"2019","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/bjophthalmol-2020-318690","article-title":"Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study","volume":"106","author":"Liu","year":"2022","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Comyn O Sivaprasad S Peto T Neveu MM Holder GE Xing W A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study) American Journal of Ophthalmology 2014 157 5 960 70","DOI":"10.1016\/j.ajo.2014.02.019"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ajo.2013.04.026","article-title":"A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema","volume":"156","author":"Nepomuceno","year":"2013","journal-title":"American Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub7-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/2013.jamaophthalmol.91","article-title":"Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment","volume":"131","author":"Do","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study","volume":"117","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0026|cit26","unstructured":"A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/login.jsp"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0027|cit27","unstructured":"A 12-month, two-armed, randomized, double-masked, multicenter, phase IIIb study assessing the efficacy and safety of laser photocoagulation as adjunctive to ranibizumab intravitreal injections vs. laser photocoagulation monotherapy in patients with visual impairment due to diabetic macular edema followed by a 12 month follow up period clinicaltrials.gov\/show\/NCT01131585"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0028|cit28","unstructured":"A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/login.jsp"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"Massin","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Berger A Sheidow T Li R Rehel B De Takacsy F Courseau AS A Canadian 12-month, phase IIIb study of ranibizumab combination or monotherapy in visual impairment due to diabetic macular edema: Preliminary analysis (\"RESPOND\") 16th Annual Canadian Diabetes Association\/Canadian Society of Endocrinology and Metabolism Professional Conference and Annual Meetings; 2013 Oct 17-19; Montreal 2013","DOI":"10.1016\/j.jcjd.2013.08.140"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0031|cit31","unstructured":"A Canadian 12-month, prospective, randomized, open-label, multicenter, phase IIIb study assessing the efficacy, safety and cost of ranibizumab as combination and monotherapy in patients with visual impairment due to diabetic macular edema Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/login.jsp"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0032|cit32","first-page":"805","article-title":"Erratum: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: Three year randomized trial results (Ophthalmology 2012;119:2312-8)","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0033|cit33","doi-asserted-by":"crossref","unstructured":"Lang GE Berta A Eldem BM Simader C Sharp D Holz FG Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study Ophthalmology 2013 120 10 2004 12","DOI":"10.1016\/j.ophtha.2013.02.019"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Mitchell P Annemans L Gallagher M Hasan R Thomas S Gairy K Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial British Journal of Opthalmology 2012 96 5 688 93","DOI":"10.1136\/bjophthalmol-2011-300726"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"615\u201362","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamaophthalmol.2013.4592","article-title":"Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial","volume":"131","author":"Mitchell","year":"2013","journal-title":"JAMA Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub7-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","article-title":"Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","article-title":"Ranibizumab 0.5\u2005mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study","volume":"100","author":"Pr\u00fcnte","year":"2016","journal-title":"British Journal of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub7-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.ophtha.2015.02.006","article-title":"The REVEAL Study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema","volume":"122","author":"Ishibashi","year":"2015","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.ophtha.2014.07.008","article-title":"Vision-related function after ranibizumab treatment for diabetic macular edema: results from RIDE and RISE","volume":"121","author":"Bressler","year":"2014","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0043|cit43","unstructured":"Mieler WF Kim JE Yau L Ehrlich JS Earlier treatment is important in diabetic macular edema: Outcomes from phase III trials of intravitreal ranibizumab 73rd Scientific sessions of the American Diabetes Association; 2013 Jun 21-25; Chicago 2013"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub7-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/IAE.0b013e31822f55de","article-title":"Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema","volume":"32","author":"Soheilian","year":"2012","journal-title":"Retina"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/IAE.0b013e31815ec261","article-title":"Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema","volume":"27","author":"Soheilian","year":"2007","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ophtha.2009.01.011","article-title":"Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema","volume":"116","author":"Soheilian","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"ophthalmology"},{"issue":"10326","key":"10.1002\/14651858.CD007419.pub7-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE):two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0051|cit51","unstructured":"Afridi R Agarwal A Sadiq MA Aggarwal K Hassan M Soliman MK Effects of two different doses of Ranibizumab on the resolution and recurrence of diabetic macular edema in the Ranibizumab for edema of the macula in diabetes (READ-3) study Investigative Ophthalmology and Visual Science 2016 57 12 ARVO E abstract 2111"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00417-007-0688-0","article-title":"Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial","volume":"246","author":"Ahmadieh","year":"2008","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub7-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamaophthalmol.2013.143","article-title":"Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema","volume":"131","author":"Ahmadieh","year":"2013","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Azad R Sain S Sharma YR Mahajan D Comparison of intravitreal bevacizumab, intravitreal triamcinolone acetonide, and macular grid augmentation in refractory diffuse diabetic macular edema: A prospective, randomized study Oman Journal of Ophthalmology 2012 5 3 166 70","DOI":"10.4103\/0974-620X.106100"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.oret.2020.02.008","article-title":"Bevacizumab and ranibizumab in diabetic macular edema study group. Comparing the efficacy of bevacizumab and ranibizumab in patients with diabetic macular edema (BRDME): the BRDME study, a randomized trial","volume":"4","author":"Vader","year":"2020","journal-title":"Ophthalmology Retina"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0057|cit57","first-page":"706","article-title":"Effect analysis of ranibizumab with laser photocoagulation therapy for diabetic macular edema","volume":"16","author":"Chen","year":"2016","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0058|cit58","unstructured":"A randomized controlled trial to compare the efficacy and safety of 1) macular laser vs. 2) repeated intravitreal bevacizumab vs. 3) combined repeated intravitreal bevacizumab with macular laser for diabetic macular edema www2.ccrb.cuhk.edu.hk\/registry\/public\/123"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0059|cit59","unstructured":"Cornish EE Teo KY Gillies MC McAllister I Sanmugasundram S Five year outcomes of the bevordex study (a multicenter randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone) Investigative Ophthalmology and Visual Science 2018 59 9 ARVO E abstract 4847"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/bjophthalmol-2021-319839","article-title":"Five-year outcomes of eyes initially enrolled in the 2-year BEVORDEX trial of bevacizumab or dexamethasone implants for diabetic macular oedema","volume":"107","author":"Cornish","year":"2023","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0061|cit61","unstructured":"Open-label, multicenter, study of the efficacy and safety of Lucentis\u00ae (ranibizumab 0.5 mg) in diabetic patients presenting a visual impairment due to diabetic macular edema in current medical practice (LUDIC) Novartis clinical trial results database. www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=9803"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0062|cit62","unstructured":"RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicentre, single-arm Phase IIIb study, with 12-month primary endpoint, assessing the efficacy and safety of Ranibizumab in patients with visual impairment Novartis clinical trial results database www.novctrd.com\/ctrdWebApp\/clinicaltrialrepository\/public\/products.jsp?divisionId=2&diseaseAreaID=12"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0063|cit63","unstructured":"An open-label, prospective, multicenter, uncontrolled, Proof of concept study assessing the efficacy of Lucentis (ranibizumab) administered by an individualized \u201ctreat and extend\u201d dosing regimen in patients with visual impairment due to dIabetic macular edema Novartis clinical trial results database. www.novctrd.com\/CtrdWeb\/displaypdf.nov?trialresultid=10423"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0064|cit64","first-page":"1942","article-title":"Clinical effect of Conbercept intravitreal injection combined with 577nm micro-pulse laser on the treatment of diabetic macular edema","volume":"15","author":"Ding","year":"2015","journal-title":"International Eye Science"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema","volume":"114","author":"Scott","year":"2007","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1097\/IAE.0b013e318217d739","article-title":"Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal\/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation","volume":"31","author":"Googe","year":"2011","journal-title":"Retina"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0067|cit67","doi-asserted-by":"crossref","unstructured":"Diabetic Retinopathy Clinical Research Network Elman MJ Qin H Aiello LP Beck RW Bressler NM Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 2012 119 11 2312 8","DOI":"10.1016\/j.ophtha.2012.08.022"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.3928\/23258160-20181101-17","article-title":"Monthly versus treat-and-extend ranibizumab for diabetic macular edema: a prospective, randomized trial","volume":"49","author":"Eichenbaum","year":"2018","journal-title":"Ophthalmic Surgery, Lasers and Imaging Retina"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1177\/112067210801800614","article-title":"Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema","volume":"18","author":"Faghihi","year":"2008","journal-title":"European Journal of Ophthalmology"},{"issue":"15","key":"10.1002\/14651858.CD007419.pub7-BIB0070|cit70","first-page":"909","article-title":"Efficacy of intravitreal injection of Bevacizumab with laser photocoagulation for diabetic macular edema","volume":"16","author":"Fang","year":"2016","journal-title":"International Eye Science"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/OPTH.S131381","article-title":"Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema","volume":"23","author":"Fouda","year":"2017","journal-title":"Clinical Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0073|cit73","unstructured":"Gillies MC Lim LL Campain AE Mehta H Quin G Fraser-Bell S BEVORDEX- A multicentre randomized clinical trial of intravitreal dexamethasone versus intravitreal bevacizumab for persistent diabetic macular edema Investigative Ophthalmology and Visual Science 2015 56 7 ARVO E abstract 3144"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0074|cit74","first-page":"493","article-title":"Clinical study of grid pattern laser photocoagulation with ranibizumab for diabetic macular edema","volume":"16","author":"Huang","year":"2016","journal-title":"International Eye Science"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0075|cit75","first-page":"773","article-title":"Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema","volume":"118","author":"Ishibashi","year":"2014","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0076|cit76","unstructured":"A phase 3 study to compare the efficacy and safety of 0.3 mg pegaptanib sodium to sham Injections In subjects with diabetic macular edema clinicaltrials.gov\/show\/NCT01100307"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2298\/VSP140402074J","article-title":"Intravitreal bevacizumab injection alone or combined with macular photocoagulation compared to macular photocoagulation as primary treatment of diabetic macular edema","volume":"72","author":"Jovanovi\u0107","year":"2015","journal-title":"Vojnosanitetski Pregled"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub7-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/IAE.0000000000001363","article-title":"Combined intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema: two-year randomized single-blind controlled trial results","volume":"37","author":"Lafuente","year":"2017","journal-title":"Retina"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/IAE.0000000000002114","article-title":"Three-year outcomes in a randomized single-blind controlled trial of intravitreal ranibizumab and oral supplementation with docosahexaenoic acid and antioxidants for diabetic macular edema","volume":"39","author":"Lafuente","year":"2019","journal-title":"Retina"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0080|cit80","first-page":"643","article-title":"Evaluation on efficacy and safety of combination treatment with intravitreal injection of ranibizumab and laser photocoagulation for diabetic macular edema","volume":"41","author":"Li","year":"2015","journal-title":"Journal of Jilin University Medicine Edition"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0081|cit81","first-page":"115","article-title":"Efficacy and safety profile of ranibizumab versus laser photocoagulation in patients with diabetic macular edema. Re-Des Study","volume":"232","author":"Lopez-Galvez","year":"2014","journal-title":"Ophthalmologica"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Adamis","year":"2005","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1167\/iovs.11-7613","article-title":"Changes in vision and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham","volume":"52","author":"Loftus","year":"2011","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ophtha.2011.02.045","article-title":"A phase 2\/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema","volume":"118","author":"Sultan","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0085|cit85","unstructured":"Efficacy study of lucentis in the treatment of diabetic macular edema \u2013 a phase II, single center, randomized study to evaluate the efficacy of ranibizumab versus focal laser treatment in subjects with diabetic macular edema clinicaltrials.gov\/show\/NCT00387582"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0086|cit86","unstructured":"Intravitreal bevacizumab and intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema (IBeTA) clinicaltrials.gov\/show\/NCT00997191"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0087|cit87","unstructured":"PF-04523655 dose escalation study, and evaluation of PF-04523655 with\/without ranibizumab in diabetic macular edema (DME) (MATISSE) clinicaltrials.gov\/ct2\/show\/study\/NCT01445899"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0088|cit88","unstructured":"A randomized, multi-center, phase II study of the safety, tolerability, and bioactivity of repeated intravitreal injections of iCo-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in the treatment of diabetic macular edema (the iDEAL Study) (iDEAL) clinicaltrials.gov\/ct2\/show\/study\/NCT01565148"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0089|cit89","unstructured":"Comparing the effectiveness and costs of bevacizumab to ranibizumab in patients with diabetic macular edema (BRDME) (BRDME) clinicaltrials.gov\/ct2\/show\/NCT01635790"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0090|cit90","unstructured":"A phase 2 randomized, controlled, double-masked, multicenter clinical trial designed to evaluate the safety and exploratory efficacy of Luminate\u00ae (ALG-1001) as compared to Avastin\u00ae and focal laser photocoagulation in the treatment of diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02348918"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0091|cit91","unstructured":"The effect of bevacizumab and ziv-aflibercept in diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02645734"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0092|cit92","unstructured":"Anti-vasculaR endothelial growth factor plUs anti-angiopoietin 2 in fixed comBination therapY: evaluation for the treatment of diabetic macular edema clinicaltrials.gov\/ct2\/show\/NCT02712008"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0093|cit93","unstructured":"Bevacizumabe or triamcinolone for persistent diabetic macular edema (BEVATAAC) clinicaltrials.gov\/ct2\/show\/NCT02985619"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bjo.2007.129122","article-title":"Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)","volume":"92","author":"Paccola","year":"2008","journal-title":"British Journal of Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub7-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjophthalmol-2020-316176","article-title":"Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results","volume":"105","author":"Payne","year":"2021","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10792-014-9967-z","article-title":"Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial","volume":"35","author":"Soheilian","year":"2015","journal-title":"International Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/IAE.0b013e3181e1ed07","article-title":"Intravitreal bevacizumab and\/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema","volume":"30","author":"Solaiman","year":"2010","journal-title":"Retina"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jdiacomp.2015.03.009","article-title":"Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?","volume":"29","author":"Turkoglu","year":"2015","journal-title":"Journal of Diabetes and its Complications"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology."},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2015.11.021","article-title":"A crossover design for comparative efficacy: a 36-week randomized trial of bevacizumab and ranibizumab for diabetic macular edema","volume":"123","author":"Wiley","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/bjophthalmol-2012-302451","article-title":"Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema","volume":"97","author":"Zehetner","year":"2013","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0102|cit102","unstructured":"This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) clinicaltrials.gov\/ct2\/show\/NCT04108156"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0103|cit103","unstructured":"A study to evaluate the efficacy, durability, and safety of ksi-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLIMMER) clinicaltrials.gov\/ct2\/show\/NCT04603937"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0104|cit104","unstructured":"A trial to evaluate the efficacy, durability, and safety of ksi-301 compared to aflibercept in participants with diabetic macular edema (DME) (GLEAM) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04611152"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0105|cit105","unstructured":"A study to evaluate the long-term safety and tolerability of faricimab in participants with diabetic macular edema (Rhone-X) clinicaltrials.gov\/ct2\/show\/NCT04432831"},{"issue":"8","key":"10.1002\/14651858.CD007419.pub7-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMe058142","article-title":"Angiogenic pathways in diabetic retinopathy","volume":"353","author":"Aiello","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08820539909069541","article-title":"The pathogenesis of edema in diabetic maculopathy","volume":"14","author":"Antcliff","year":"1999","journal-title":"Seminars in Ophthalmology"},{"issue":"6921","key":"10.1002\/14651858.CD007419.pub7-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration","volume":"308","year":"1994","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11096-013-9779-7","article-title":"Bevacizumab versus ranibizumab: why are we not playing the joker?","volume":"35","author":"Banfi","year":"2013","journal-title":"International Journal of Clinical Pharmacy"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmology. Retina"},{"issue":"7","key":"10.1002\/14651858.CD007419.pub7-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jclinepi.2008.09.013","article-title":"The evidence provided by a single trial is less reliable than its statistical analysis suggests","volume":"62","author":"Borm","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.122.3.330","article-title":"Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography","volume":"122","author":"Brown","year":"2004","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub7-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ajo.2008.07.013","article-title":"Diabetic macular edema: what is focal and what is diffuse?","volume":"146","author":"Browning","year":"2008","journal-title":"American Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1002\/14651858.CD007419.pub7-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Maguire","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0119|cit119","unstructured":"Chaimani A Caldwell DM Li T Higgins JPT Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2337\/diacare.26.9.2653","article-title":"Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies","volume":"26","author":"Ciulla","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.icu.0000120711.35941.76","article-title":"Corticosteroids in posterior segment disease: an update on new delivery systems and new indications","volume":"15","author":"Ciulla","year":"2004","journal-title":"Current Opinions in Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD007419.pub7-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.ophtha.2005.06.007","article-title":"A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema","volume":"112","author":"Adamis","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0123|cit123","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0125|cit125","unstructured":"European Medicines Agency Ozurdex Product Information Available at www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozurdex"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0126|cit126","unstructured":"European Medicines Agency Lucentis Product Information Available at www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lucentis"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0127|cit127","unstructured":"European Medicines Agency Eylea Product Information Available at www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eylea"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0128|cit128","unstructured":"European Medicines Agency Beovu European public assessment report Available at www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beovu"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","article-title":"Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1","volume":"103","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1985","journal-title":"Archives of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0130|cit130","unstructured":"EYLEA (afilbercept) injection label Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125387lbl.pdf"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0131|cit131","unstructured":"LUCENTIS (ranibizumab injection) label Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125156s105lbl.pdf"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0132|cit132","unstructured":"Drug Approval Package: BEOVU (brolucizumab-dbll) Available at www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761125_Orig1_toc.cfm"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0133|cit133","unstructured":"VABYSMO Highlights of prescribing information Available at www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761235s000lbl.pdf"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra021678","article-title":"Diabetic retinopathy","volume":"350","author":"Frank","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub7-BIB0135|cit135","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0136|cit136","first-page":"12001","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study)","volume":"1272","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0137|cit137","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005656.pub2","article-title":"Intravitreal steroids for macular edema in diabetes","author":"Grover","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archophthalmol.2010.21","article-title":"Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema","volume":"128","author":"Haller","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","article-title":"Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: extrapolation of data to clinical practice","volume":"134","author":"Heier","year":"2016","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0141|cit141","unstructured":"Higgins JP Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0142|cit142","unstructured":"Higgins JP Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2\/"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1517\/14712598.2016.1131265","article-title":"Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy","volume":"16","author":"Hussain","year":"2016","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"22","key":"10.1002\/14651858.CD007419.pub7-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2014.2536","article-title":"Revolution to a new standard treatment of diabetic macular edema","volume":"311","author":"Jampol","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"735","DOI":"10.18553\/jmcp.2015.21.9.735","article-title":"Treatment patterns of anti-vascular endothelial growth factor and laser therapy among patients with diabetic macular edema","volume":"21","author":"Jiang","year":"2015","journal-title":"Journal of Managed Care and Specialty Pharmacy"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/jamaophthalmol.2021.4585","article-title":"Safety outcomes of brolucizumab in neovascular age-related macular degeneration: results from the IRIS Registry and Komodo Healthcare Map","volume":"140","author":"Khanani","year":"2022","journal-title":"JAMA Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema","volume":"91","author":"Klein","year":"1984","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub7-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/archophthalmol.2010.44","article-title":"Intravitreous dexamethasone effects on different patterns of diabetic macular edema","volume":"128","author":"Kuppermann","year":"2010","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub7-BIB0150|cit150","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012208.pub2","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","author":"Li","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2022.08.012","article-title":"DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser (DIAMONDS): A randomized double-masked non-inferiority clinical trial","volume":"130","author":"Lois","year":"2023","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD007419.pub7-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0153|cit153","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","author":"Moja","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12886-018-1006-9","article-title":"An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data","volume":"18","author":"Muston","year":"2018","journal-title":"BMC Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Medicine"},{"issue":"51","key":"10.1002\/14651858.CD007419.pub7-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17510","article-title":"Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study","volume":"17","author":"Olson","year":"2013","journal-title":"Health Technology Assessment"},{"issue":"13","key":"10.1002\/14651858.CD007419.pub7-BIB0157|cit157","first-page":"1","article-title":"Optical coherence tomography for age-related macular degeneration and diabetic macular edema: an evidence-based analysis","volume":"9","author":"Medical Advisory Secretariat","year":"2009","journal-title":"Ontario Health Technology Assessment Series"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/eye.2015.214","article-title":"A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study)","volume":"29","author":"Ramu","year":"2015","journal-title":"Eye"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"Article ID 8571","DOI":"10.1155\/2014\/857148","article-title":"A 2-year, phase IV, multicentre, observational study of ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration in routine clinical practice: the EPICOHORT study","volume":"2014","author":"Pagliarini","year":"2014","journal-title":"Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD007419.pub7-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40259-021-00499-2","article-title":"Anti-VEGF and other novel therapies for neovascular age-related macular degeneration: an update","volume":"35","author":"Parravano","year":"2021","journal-title":"BioDrugs"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ajo.2016.09.002","article-title":"Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting","volume":"172","author":"Patrao","year":"2016","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"e14746","DOI":"10.1111\/dme.14746","article-title":"Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: a real-world study","volume":"39","author":"Peto","year":"2022","journal-title":"Diabetic Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007419.pub7-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/j.ophtha.2013.02.018","article-title":"Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema","volume":"120","author":"Callanan","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.oret.2021.12.019","article-title":"Frequency of intravitreal anti-VEGF injections and risk of death: a systematic review with meta-analysis","volume":"6","author":"Reibaldi","year":"2022","journal-title":"Ophthalmology. Retina"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0165|cit165","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"2","key":"10.1002\/14651858.CD007419.pub7-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub7-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.survophthal.2022.04.003","article-title":"Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: a systematic review and meta-analysis of 2,346 eyes","volume":"67","author":"Sarohia","journal-title":"Survey of Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0168|cit168","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0169|cit169","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions.In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0170|cit170","unstructured":"Stata StataCorp 2021"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2016.05.023","article-title":"Counterfeit Avastin in India: punish the criminals, not the patients","volume":"170","author":"Stewart","year":"2016","journal-title":"American Journal of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00417-022-05703-9","article-title":"Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes","volume":"260","author":"Sugimoto","year":"2022","journal-title":"Graefes Archives of Clinical Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0173|cit173","unstructured":"National Institute for Clinical Excellence (NICE) - Technology appraisal guidance Ranibizumab for treating diabetic macular oedema www.nice.org.uk\/guidance\/ta274"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0174|cit174","unstructured":"National Institute for Clinical Excellence (NICE) - Technology appraisal guidance Aflibercept for treating diabetic macular oedema www.nice.org.uk\/guidance\/ta346"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0175|cit175","unstructured":"National Institute for Clinical Excellence (NICE) - Technology appraisal guidance Faricimab for treating diabetic macular oedema www.nice.org.uk\/guidance\/ta799"},{"issue":"5","key":"10.1002\/14651858.CD007419.pub7-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0039-6257(04)00109-2","article-title":"Macular edema","volume":"49","author":"Tranos","year":"2004","journal-title":"Survey of Ophthalmology"},{"issue":"876386","key":"10.1002\/14651858.CD007419.pub7-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2022.876386","article-title":"Different anti-vascular endothelial growth factor for patients with diabetic macular edema: a network meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata Journal"},{"issue":"3","key":"10.1002\/14651858.CD007419.pub7-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nu\u00f1ez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"637667","DOI":"10.3389\/fphar.2021.637667","article-title":"Efficacy of antiangiogenic drugs in the treatment of diabetic macular edema: a bayesian network analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD007419.pub7-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","article-title":"Demographics of patients receiving Intravitrealanti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials","volume":"17","author":"Ziemssen","year":"2017","journal-title":"BMC Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1007\/s00417-021-05187-z","article-title":"Long-term outcomes of intravitreal therapy for symptomatic diabetic macular oedema in a real-world setting in Switzerland","volume":"259","author":"Zirpel","year":"2021","journal-title":"Graefes Archives of Clinical and Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","author":"Parravano","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007419.pub7-BIB0185|cit185","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub2","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","author":"Parravano","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD007419.pub7-BIB0186|cit186","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub3","article-title":"Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema","author":"Virgili","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD007419.pub7-BIB0187|cit187","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub4","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","author":"Virgili","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10 CD007419","key":"10.1002\/14651858.CD007419.pub7-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub6","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","author":"Virgili","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T10:19:53Z","timestamp":1762856393000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007419.pub7"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":188,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007419.pub7","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]}}}